Navigation Links
Revlimid Approved For Treatment Of Myelodysplastic Syndrome (MDS) by FDA

A new drug treatment, Revlimid for treatment of myelodysplastic syndrome (MDS), a rare blood disorder has been approved by the Food and Drug Administration (FDA). The approval was announced by Celgene Corp, manufacturer of the drug.//

The exact cause of MDS is not known. However, increased incidence of MDS has been noticed following radiotherapy or chemotherapy. Transfusion of blood and blood products (platelet) is the usual form of treatment. Anti-biotics may also be given to treat the associated infection.

Symptoms of MDS include fatigue, generalized weakness, susceptibility to infections, bleeding tendency and fever. The incidence of MDS is as high as 7000 to 12000 in the United States with a majority of the cases diagnosed in patients over 60 years.

The new drug has been approved by the FDA, owing to its improved performance in clinical trials. The need for a blood transfusion was eliminated in patients treated with Revlimid. Infact, following 3 months of therapy, a majority of the patients became independent of transfusions. This effect was observed for an average of 44 weeks.

The new drug closely resembles another drug, Thalomid, known to cause severe birth defects when administered to the pregnant mother. On account of this structural similarity, a ‘black box’ warning would be issued to prevent fetal exposure to Revlimid.

The drug would further be marketed under a strict adherence to a risk-management strategy, called RevAssist. According to the plan, only registered participants of the program (doctors and pharmacists) would be authorized to prescribe or market Revlimid. This is expected to reduce the probability of fetal exposure to the teratogenic drug.


'"/>




Page: 1

Related medicine news :

1. Revlimid Approved By FDA For Multiple Myeloma
2. Levothyroxine Thyroid Hormone Replacement, Approved for Hypothyroidism
3. New FDA Approved Drug To Treat Migraine
4. New FDA Approved Drug NATRECOR For Heart Failure Patients
5. New Oral Rinse For Gingivitis Approved By FDA
6. Child Friendly Zidovudine Preparation for treating HIV infection Approved By The FDA
7. AIDS Generic Drugs Approved by FDA for Sale in US
8. FDA Approved Nerve-Stimulation Therapy Now Available In New York
9. Pfizer’s Eraxis Approved By The FD
10. Inhalers for Kids Was Approved By the FDA
11. Alcoholism Drug Vivitrol Approved By FDA
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:4/29/2016)... ... April 29, 2016 , ... ... Celiac Association (CCA), is pleased to announce the launch of the GFCP ... articles, recipes, and more. The purpose of the GFCP Scoop site ...
(Date:4/29/2016)... ... April 29, 2016 , ... New York City based oral and maxillofacial surgeon Dr. ... very effective way to treat obstructive sleep apnea. Dr. Jamali is proud to offer this ... procedure that involves one or both jaw bones. This surgery is performed to correct the ...
(Date:4/29/2016)... ... April 29, 2016 , ... Jvion, the ... of funding led by Eastside Partners, with participation from existing investor Martin Ventures. ... base and accelerate its technology and product roadmap. , “Jvion is ...
(Date:4/29/2016)... ... April 29, 2016 , ... CURE ... entirely on patients with cancer, today announced that Lynne Malestic, RN, of Eisenhower ... 2016 CURE® Extraordinary Healer® for Oncology Nursing , which honors nurses who have ...
(Date:4/29/2016)... , ... April 29, 2016 , ... ... to promote their animal line of probiotics, Petbiotics ™, as they fondly ... turnout of animal rescue groups networking for their non-profit organizations. Animal rescues across ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... 28, 2016  While Abbott,s announced purchase of ... valve repair and stent business, healthcare research firm ... more firmly into patient monitoring.  Kalorama said that ... device areas, with double-digit growth expected the next ... Advanced Remote Patient Monitoring . Abbott Laboratories ...
(Date:4/28/2016)... 28, 2016 ... Phillips und Stephen Schmidt ... ArisGlobal®, ein führender Anbieter cloudbasierter Softwarelösungen ... bekannt, dass neue Führungskräfte zum Team Sicherheit ... die vielfältige Erfahrungen mitbringen.  Dies wird die ...
(Date:4/28/2016)... April 28, 2016 , Net Sales of ... basis over the prior year period, and an increase of ... , Diluted EPS for the first quarter were $0.52 reported, ... $2.00 adjusted, an increase of 29.9% over the prior year ... adjusted earnings guidance for 2016 Zimmer Biomet Holdings, ...
Breaking Medicine Technology: